Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation

Published:2019-12-31 Issue:4 Volume:54 Page:288-290
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Niscola Pasquale¹,Grazia Carmen Di²,Mazzone Carla¹,Tolu Barbara³,Fabritiis Paolo de¹,Angelucci Emanuele²

Affiliation:

1. Hematology Unit, Saint Eugenio Hospital, Tor Vergata University, Rome, Italy

2. Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genua, Italy

3. Radiation Oncology Unit, UPMC Hillman Cancer Center, San Pietro Hospital FBF, Rome, Italy

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/br.2019.54.4.288

Reference12 articles.

1. Treatment of MDS

2. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

3. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

4. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders

5. How I treat MDS after hypomethylating agent failure

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP